Patent · US Active

Complement inhibitors and uses thereof

US8221756B2 · kind B2 · utility

21Cited by
5References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 11, 2011
Grant dateJul 17, 2012
Priority date
Expiry dateMar 11, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/55
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.